Anti-TPO antibody or functional fragment thereof and application thereof

By designing specific anti-TPO antibodies or their functional fragments, the specificity and stability problems in TPO protein purification and detection calibration are solved, and efficient TPO protein binding and detection calibration is achieved, improving the accuracy of thyroid function detection.

CN119019560APending Publication Date: 2024-11-26CHONGQING ESSENCE BIOENGINEERING CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310582339.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing TPO antibody detection methods have insufficient specificity and stability, making it difficult to achieve efficient TPO protein purification and calibration, affecting the accuracy of thyroid function detection.

Method used

An anti-TPO antibody or its functional fragment was developed to improve the affinity with TPO proteins through specific complementary determination regions amino acid sequence design and applied to the purification and detection calibration products of TPO proteins.

Benefits of technology

The binding of high affinity to TPO protein is achieved, the purification efficiency of TPO protein and the accuracy of detection and calibration are improved, and a stable and reliable reference for thyroid function detection is provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019560A_ABST
    Figure CN119019560A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to an anti-TPO antibody or a functional fragment thereof and application thereof. The invention not only provides a high-affinity monoclonal antibody (wild type) combined with TPO, but also performs site-directed mutagenesis on the wild type, verifies the affinity of each mutation and related application thereof, and provides reference for research in the field of immunodetection of TPO.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an anti-TPO antibody or a functional fragment thereof and an application thereof. Background Art

[0002] Thyroid peroxidase (TPO) is a membrane-bound glycoprotein containing a heme prosthetic group. The entire molecule is divided into an intramembrane region, a transmembrane region, and an extramembrane region. The cDNA is 3kb in length. The presence of the transmembrane region makes it difficult for TPO to be secreted when expressed, and the catalytically active part extends to the interior of the colloid follicle cavity. As an important enzyme in the synthesis of thyroid hormones in the body, TPO can participate in the catalytic activation of iodine, the iodination of tyrosine residues on thyroglobulin, and the coupling process of iodinated tyrosine residues, and ultimately produce thyroxine (T3, T4). TPO is also the main antigen component of thyroid microsomes. When the thyroid gland of an organism is diseased, resulting in the destruction of the biological structure of follicular cells, TPO immediately leaks into the peripheral blood through the edge of the thyroid follicular cell cavity, that is, the top of the thyroid cell, thereby stimulating the body to regulate the immune system. The immune system then produces TPO antibodies (Anti-TPO) to respond to the stimulation.

[0003] Thyroid peroxidase antibodies (Anti-TPO) are common in people with autoimmune thyroid diseases. They are a type of thyroid autoantibody. Anti-TPO positivity is mainly seen in patients with Hashimoto's thyroiditis, primary hypothyroidism, hyperthyroidism, etc. Detection of thyroid peroxidase antibodies (Anti-TPO) in thyroid function tests has become one of the basic detection indicators of thyroid function.

[0004] At present, the development of high-quality TPO protein is very beneficial for the diagnosis of related diseases. When using chemiluminescence for quantitative detection, the sample needs to be calibrated. Stable and linear calibrators are essential for reagent development. This article uses a humanized monoclonal antibody for calibration and quality control of Anti-TPO diagnosis, which plays a vital role in quantification. Summary of the invention

[0005] The purpose of the present invention is to provide an anti-TPO antibody or a functional fragment thereof, to achieve specific binding with the TPO protein, and ultimately to be applied to the purification and detection calibration of TPO.

[0006] The details are as follows:

[0007] The anti-TPO antibody or its functional fragment has the following complementarity determining region:

[0008] CDR-VH1: S-X1-WM-X2, where X1 is Y or D, and X2 is H;

[0009] CDR-VH2: YI-X1-PTTGY-X2-DYNX 3-NFKD, wherein X1 is I or N, X2 is S or T, and X3 is Q or S;

[0010] CDR-VH3: RN-X1-RYDG-X2-YFDY, where X1 is A or Y, and X2 is R or Y; CDR-VL1: RSSQSI-X1-HSNGN-X2-YLE, where X1 is A or N, and X2 is R or A;

[0011] CDR-VL2: K-X1-SN-X2-FS, where X1 is V or H, and X2 is R or A;

[0012] CDR-VL3: F-X1-GSHVP-X2-T, wherein X1 is Q and X2 is W or P.

[0013] Furthermore, X2 of CDR-VH1 of the complementary determining region is H, X1 of CDR-VH2 is I, X2 of CDR-VH3 is R, X1 of CDR-VL1 is A, X2 of CDR-VL2 is R, and X1 of CDR-VL3 is Q.

[0014] The CDR segment division described in the present invention adopts the Kabat algorithm.

[0015] "CDR" is used herein to refer to a "complementarity determining region" within an antibody variable sequence. The variable regions of the heavy and light chains each have three CDRs, starting from the N-terminus of the heavy or light chain.

[0016] The antigen binding site may include six CDRs (CDR-VH1, CDR-VH2, CDR-VH3, CDR-VL1, CDR-VL2 and CDR-VL3 in the present invention). A polypeptide comprising a single CDR (e.g., CDR-VH1, CDR-VH2, CDR-VH3, CDR-VL1, CDR-VL2 or CDR-VL3) may be referred to as a "molecular recognition unit". Crystallographic analysis of antigen-antibody complexes has shown that the amino acid residues of CDRs form extensive contacts with the bound antigen, with the most extensive antigen contact being with the heavy chain CDR3. Therefore, the molecular recognition unit may be primarily responsible for the specificity of the antigen binding site. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.

[0017] The inventors of the present invention have found that when the mutation sites in each complementary determining region are the amino acid residues, the antibody has a better affinity for the TPO protein.

[0018] In an optional embodiment, X1 in the CDR-VH1 is Y;

[0019] In an optional embodiment, X1 in the CDR-VH1 is D;

[0020] In an optional embodiment, X2 in the CDR-VH1 is H;

[0021] In an optional embodiment, X1 in the CDR-VH2 is 1;

[0022] In an optional embodiment, X1 in the CDR-VH2 is N;

[0023] In an optional embodiment, X2 in the CDR-VH2 is S;

[0024] In an optional embodiment, X2 in the CDR-VH2 is T;

[0025] In an optional embodiment, X3 in the CDR-VH2 is Q;

[0026] In an optional embodiment, X3 in the CDR-VH2 is S;

[0027] In an optional embodiment, X1 in the CDR-VH3 is A;

[0028] In an optional embodiment, X1 in the CDR-VH3 is Y;

[0029] In an optional embodiment, X2 in the CDR-VH3 is R;

[0030] In an optional embodiment, X2 in the CDR-VH3 is Y;

[0031] In an optional embodiment, X1 in the CDR-VL1 is A;

[0032] In an optional embodiment, X1 in the CDR-VL1 is N;

[0033] In an optional embodiment, X2 in the CDR-VL1 is T;

[0034] In an optional embodiment, X2 in the CDR-VL1 is F;

[0035] In an optional embodiment, X1 in the CDR-VL2 is V;

[0036] In an optional embodiment, X1 in the CDR-VL2 is L;

[0037] In an optional embodiment, X2 in the CDR-VL2 is R;

[0038] In an optional embodiment, X2 in the CDR-VL2 is A;

[0039] In an optional embodiment, X1 in the CDR-VL3 is Q;

[0040] In an optional embodiment, X2 in the CDR-VL3 is W;

[0041] In an optional embodiment, X2 in the CDR-VL3 is P;

[0042] Preferably, each complementary determining region is selected from any one of the following mutation combinations:

[0043]

[0045]

[0046] Further, the antibody comprises light chain framework regions FR1-L, FR2-L, FR3-L and FR4-L and heavy chain framework regions FR1-H, FR2-H, FR3-H and FR4-H; the heavy chain framework regions FR1-H, FR2-H, FR3-H and FR4-H are selected from SEQ ID NOs: 1-4 in sequence; the light chain framework regions FR1-L, FR2-L, FR3-L and FR4-L are selected from SEQ ID NOs: 5-8 in sequence.

[0047] Furthermore, the antibody also comprises a constant region.

[0048] Preferably, the constant region is selected from the constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD. Preferably, the species origin of the constant region is cattle, horses, dairy cows, pigs, sheep, goats, rats, mice, dogs, cats, rabbits, camels, donkeys, deer, minks, chickens, ducks, geese, turkeys, fighting cocks or humans.

[0049] Preferably, the functional fragment is selected from any one of VHH, F(ab')2, Fab', Fab, Fv and scFv of the antibody.

[0050] Furthermore, the antibody is a labeled antibody.

[0051] The "labeled antibody" of the present invention is labeled with a detectable marker.

[0052] The term "antibody" includes various forms of antibody structures, including but not limited to complete antibodies and antibody fragments. The antibody according to the present invention is preferably a goat, sheep, mouse, rabbit or rat antibody, a chimeric antibody or a further genetically engineered antibody, as long as the characteristic properties according to the present invention are retained. "Antibody fragment" comprises a portion of a full-length antibody, preferably its variable domain, or at least its antigen binding site. Examples of antibody fragments include diabodies, single-chain antibody molecules and multispecific antibodies formed by antibody fragments. Examples of antibody fragments include Fab, Fab', F(ab')2 and Fv fragments; single-chain antibody molecules; scFv, sc(Fv)2; diabodies; and multispecific antibodies formed by antibody fragments.

[0053] Preferably, the detectable markers include, but are not limited to, biotin, fluorescent dyes, enzymes that catalyze substrate color development, radioactive isotopes, chemiluminescent agents, and nanoparticle markers;

[0054] Preferably, the fluorescent dyes include but are not limited to fluorescein dyes and their derivatives, rhodamine dyes and their derivatives, Cy series dyes and their derivatives, series dyes and their derivatives, ATTOTM series dyes, TYE series dyes, quantum dots and protein dyes and their derivatives, etc.; the enzyme is an enzyme that catalyzes the color development of the substrate, and the enzyme that catalyzes the color development of the substrate includes but is not limited to horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase and 6-phosphoglucose deoxidase;

[0055] Preferably, the enzyme that catalyzes the color development of the substrate includes, but is not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and 6-phosphoglucose deoxidase;

[0056] Preferably, the radioactive isotopes include but are not limited to 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110mIn, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu and 18F;

[0057] Preferably, the chemiluminescent reagent includes, but is not limited to, luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, bipyridine ruthenium and its derivatives, acridinium esters and their derivatives, dioxetanes and their derivatives, lophanes and their derivatives, and peroxyoxalates and their derivatives;

[0058] Preferably, the nanoparticle markers include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles;

[0059] Preferably, the colloid includes, but is not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex;

[0060] Preferably, the colloidal metal includes but is not limited to colloidal gold, colloidal silver and colloidal selenium.

[0061] In another aspect, the present invention discloses the use of the anti-TPO antibody in purifying TPO protein.

[0062] On the other hand, the present invention discloses the use of the Kang TPO antibody as a calibration quality control in a TPO antibody detection kit.

[0063] Preferably, the sample detected by the kit is selected from body fluids such as whole blood, serum, plasma, urine or saliva.

[0064] Beneficial effects:

[0065] The present invention not only provides a monoclonal antibody (wild type) with high affinity for binding to TPO, but also makes a variety of mutations with excellent performance to the wild type, which can be applied to purifying TPO protein, as a calibration quality control, etc., and provides a variety of references for immune detection reactions. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] Figure 1 :The effect of mutation 2-2 on TPO antigen purification, where the left side is the marker and the right side is the purified TPO antigen;

[0067] Figure 2 : Linearity verification of mutation 2-2 as calibrator. DETAILED DESCRIPTION

[0068] Specifically, in order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0069] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Any methods and materials similar or equivalent to those described herein can be used for the practice or testing of the preparations or unit doses herein. Unless otherwise indicated, the techniques adopted or considered herein are standard methods. Materials, methods and examples are illustrative and non-restrictive only.

[0070] As used herein, the terms "including," "comprising," "having," "may," and variations thereof are intended to be open-ended transitional phrases, terms, or words that do not exclude the possibility of additional actions or structures.

[0071] Unless otherwise indicated, the practice of the present invention will employ conventional techniques of cell biology, molecular biology (comprising recombinant technology), microbiology, biochemistry and immunology, which are within the capabilities of those skilled in the art. This technology is fully explained in the literature, such as "Molecular Cloning: A Laboratory Manual", Second Edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (MJ Gait, 1984); "Animal Cell Culture" (RI Freshney, 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (DM Weir and CC Black, 1989). ell, ed.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.

[0072] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0073] Example 1 Preparation of monoclonal antibodies

[0074] A. Expression and purification of thyroid peroxidase (TPO)

[0075] The gene sequence of the first 19-846aa of human TPO protein was cloned into the pfastbac1 vector, and the Melittin signal peptide was added to the N-terminus and transferred into DH10bac to screen for white spot clones for plasmid extraction, and then transferred into SF9 cells to prepare viruses. After the viruses were obtained, they were transferred into H.five cells for expression. Finally, the TPO protein with a purity greater than 80% was purified using the his tag for immunization.

[0076] (I) DH10bac transformation

[0077] 1. Take 100 μl of DH10bac competent cells and place on ice for 10 minutes until completely thawed. Add 50-200 ng (about 1 μl) of plasmid and mix gently, and place on ice for 30 minutes;

[0078] 2. Heat shock at 42°C for 45 seconds;

[0079] 3. Place on ice for 2-5 minutes;

[0080] 4. Add 700 μl LB medium and incubate at 37°C, 225 rpm for 4 h;

[0081] 5. Take 100 μl of the plate coated with X-gal and incubate it upside down at 37°C overnight;

[0082] 6. Take the white colonies and streak them on the x-gal plate, then invert and culture them at 37℃ overnight;

[0083] 7. If the colonies remain white after overnight observation, the transformation is considered successful. Colony PCR can also be performed for further verification.

[0084] (II) Extraction of rod-shaped plasmid

[0085] 1. Pick the white clones and place them in 2 ml LB medium (50 μg / ml kanamycin, 7 μg / ml gentamicin, 10 μg / ml tetracycline, X-gal 100 μg / ml, IPTG 40 μg / ml), and culture at 37°C in a shaker at 250-300 rpm for more than 24 hours;

[0086] 2. Extract bacmid using PureLink HiPure Plasmid DNA Purification Kits;

[0087] 3. After extraction, dissolve the plasmid in water and set aside after the concentration is greater than 500ng / μl.

[0088] 3. Virus preparation and amplification

[0089] 1. Take out Sf9 cells from liquid nitrogen for resuscitation, culture them in T25 culture flasks (anti / anti added to the culture medium), and culture them statically at 28°C for about 72 hours.

[0090] 2. When the confluence of Sf9 cells in the T25 culture flask reaches 90%-100%, remove the old culture medium, add 15ml of fresh culture medium, and inoculate into new T25 culture flasks at a ratio of one to three, 4ml / T25 culture flask (no anti / anti is added to the culture medium). Incubate in a 28℃ dry incubator for 24h.

[0091] 2. Preparation of transfection mixture: Add 2 μg of bacmid DNA to 200 μl Sf900II culture medium, add 10 μg of transfection reagent to 200 μl Sf900II culture medium, then gently mix the prepared bacmid DNA working solution and transfection reagent working solution, incubate at room temperature for 20 minutes, add to 4 ml of SF9 cell solution, and then place in a 28°C incubator for static culture.

[0092] 3. Observe the cell status 24 hours after transfection. Complex particles can be seen to check whether there is contamination so that timely response can be taken.

[0093] 4. After 72 hours of transfection, obvious cell lesions can be seen, and the cells become round and enlarged. Collect the supernatant after 3-5 days and centrifuge at 1500rpm / min at room temperature. Filter the supernatant with a 0.22um filter and define it as TPO-P0 generation virus, store it at 4℃ for short term (valid for three months) and -20℃ for long term (valid for one year). Residual cells can be analyzed by WB to detect whether TPO is expressed. After confirming the expression, continue to amplify the TPO-P1 generation virus.

[0094] 5. The seeding density is 1.5×10 6 A total of 30 ml of Sf9 cells (viability greater than 95%) were placed in a 125 ml shake flask. The P0 virus was calculated according to the titer of 1E6 and MOI = 0.05, and added to the Sf9 cells and cultured at 28°C. Cytopathic effects can be observed after 72 hours. The supernatant was collected after 3-4 days and centrifuged at 1500 rpm / min at room temperature. The supernatant was filtered with a 0.22um filter and defined as TPO-P1 generation virus. After subsequent titer determination, it can be directly used for large-scale amplification of TPO-P2 generation virus.

[0095] 6. The seeding density is 1.5×10 61000 ml of SF9 cells (viability greater than 95%) were placed in a 2.8L shake flask. P1 virus was calculated according to the titer of 1E7 and MOI = 0.05, and added to Sf9 cells and cultured at 28°C. Cytopathic effects can be observed after 72 hours. The supernatant was collected after 3-4 days and centrifuged at 1500 rpm / min at room temperature. The supernatant was filtered with a 0.22um filter and defined as TPO-P2 generation virus. After subsequent titer determination, it can be directly used for large-scale infection to express TPO protein.

[0096] 7. Use the fluorescent quantitative PCR method to determine the titer, use the TPO standard plasmid as the standard, extract the TPO-P2 virus DNA as a sample for titer quantification, and the virus titer greater than 1E8 can be used

[0097] (IV) Fermentation expression process

[0098] 1. Shake flask fermentation

[0099] 1. Preparation of H.five cell suspension:

[0100] a. Shake the cell suspension evenly, use a pipette to aspirate about 1 ml and add it into a sterile 1.5 ml EP tube, aspirate 10 μl of the cell suspension and mix it with 10 μl of trypan blue, pipette 10 μl into a cell counting plate, put it into a cell counter for automatic counting, and observe the cell status under a microscope.

[0101] b. The cell transfection density is 3E6 and the volume is 1L; calculate the required volume of cell suspension based on the number of live cells, transfer the cell suspension to a 50ml sterile centrifuge tube, centrifuge at 800rpm / min for 5min, collect the cells, pour out most of the old culture medium, leaving 5-10ml of old culture medium / tube, resuspend the cells, pour into a 2.8L shake flask, add 45ml of 200mM glutamine (9mM) to 1L of fresh culture medium for H.five cells, and pour the culture medium containing 9mM glutamine into the 2.8L shake flask to a final volume of 1L.

[0102] 2. Virus infection:

[0103] a. Add virus to the prepared H.five cells. Required virus = cell density × volume × MOI / virus titer

[0104] b. According to the calculation results, gently invert and mix the virus, add TPO-P2 virus at MOI = 2, gently mix, and place in a dry incubator at 28°C, 120rpm / min for shaking suspension culture. The fermentation process lasts for 72 hours, and the changes in cell dynamic parameters are monitored every 24 hours, and samples are collected after 3 days.

[0105] 3. Pour the fermentation broth into a 250ml centrifuge bottle, balance it, place it in a centrifuge at 3000rpm / min, 4℃ for 10min, collect the supernatant, and measure to confirm the final volume. Add PMSF with a final concentration of 1mM / L to the supernatant, and store the fermentation broth at 4℃ for purification.

[0106] (IV) Purification process

[0107] 1. After centrifugation, purify through Ni excel column;

[0108] 2. Elution with 200 mM imidazole;

[0109] 3.4°C dialyzed into a buffer of 50 mM Tris, 150 mM NaCl, 0.1 mM potassium iodide, pH 7.6;

[0110] 4. Quantification was performed using the BCA method (Pierce™ BCA Protein Assay Kit, invitrogen, catalog number: 23227).

[0111] B. Mouse immunization and antibody detection

[0112] Select 5 6-8 week old SPF female BALB / c mice, mix and emulsify Freund's complete adjuvant and TPO protein at a concentration of 2 mg / ml in equal volumes. Use the emulsified antigen to immunize 6-8 week old SPF female BALB / c mice, and inject 40 μg of antigen protein into each mouse by subcutaneous injection in the foot or back. Two weeks after the first immunization, mix and emulsify the antigen protein with Freund's incomplete adjuvant, and inject 40 μg of antigen protein into each mouse by subcutaneous injection in the foot or back. Two weeks later, collect blood through the tail vein, collect the supernatant by centrifugation, and test the serum titer by ELISA. Immunize and test the serum titer every two weeks. After two immunizations, the serum titer is as high as 2.0 or above after a million-fold dilution. Screening serum titer 10 6 Lymph was taken from the above mice to separate lymphocytes for cell fusion.

[0113] C. Cell fusion, positive hybridoma cell screening and subcloning

[0114] Lymphocytes from isolated immunized mice were fused with cultured SP2 / 0 cells by PEG1500 or electrofusion. The fused cells were cultured in HAT-1640 medium containing 20% ​​FBS serum for screening. The culture medium was replaced after one week, and the culture supernatant was taken after 4 days of culture for positive clone screening. Positive wells were screened using TPO. Wells with a higher ratio of ELISA positive value to cell number were selected for multiple subcloning. ELISA plates were coated with TPO protein. The culture supernatant of the subclones was taken to screen monoclones that could show affinity under antigen coating conditions, and the monoclonal hybridoma cells with the highest affinity were selected from them. Finally, a hybridoma cell line with a high antibody titer that could secrete TPO monoclonal antibodies was obtained, named 17#, which had good stability.

[0115] D. Production and purification of monoclonal antibodies

[0116] Two groups of 6-8 week old BALB / c mice were selected and injected intraperitoneally with 500 μL paraffin oil to suppress the immune response of mice. One week after the injection, 0.5 ml of cell 17# was injected into the peritoneal cavity of the mice. The number of cells was about 1×10 6 After two weeks, ascites was collected. The collected ascites was precipitated with ammonium sulfate and affinity purified with protein A to obtain the target antibody 17#.

[0117] E. Identification of monoclonal antibody subtypes and gene sequence cloning

[0118] The SBA Clonotyping System-HRP kit from Southern Biothech was used to identify the subtypes of the heavy and light chains of the monoclonal antibody according to the instructions. The specific operations were as follows:

[0119] 1. Dilute the capture antibody to 1 μg / mL with coating solution (0.05M carbonate and bicarbonate buffer at pH 9.5), add 100 μL / well to the ELISA plate, and coat overnight at 4°C. Wash the plate three times with PBS buffer (washing solution) containing 0.05% Tween-20.

[0120] 2. Dilute the culture supernatant of the hybridoma cells to be tested with diluent (1% BSA, 0.1% PBST) at a ratio of 1:1, add 100 μL / well to the ELISA plate, and incubate at 37°C for 30 minutes. Dilute the corresponding enzyme-labeled antibodies (Ig-HRP, IgG1-HRP, IgG2a-HRP, IgG2b-HRP, IgG3-HRP, IgM-HRP, kappa-HRP, lamda-HRP) at a ratio of 1:3000 with diluent.

[0121] 3. After washing the plate 3 times with the plate washing solution, add 100 μL of diluted enzyme-labeled antibody to each well and incubate at 37°C for 30 minutes. After washing the plate 3 times again, add the color developing solution. After about 5 minutes (depending on the strength of the reaction), add 2M sulfuric acid to terminate the reaction and read the OD450 absorbance. After identification, the heavy chain subtype of antibody 17# is IgG1, and the light chain is Kappa.

[0122] According to the antibody subtype results, the antibody gene sequence was cloned using a RACE-based method. Hybridoma cells with good growth were collected, and total RNA of hybridoma cells was obtained using a total RNA extraction kit. The mRNA was reverse transcribed into cDNA according to the operating method of Takara's SMARTer RACE manual, and the full-length sequence of the target antibody was amplified.

[0123] Example 2 Verification of antibody performance

[0124] 1. ELISA affinity test

[0125] Dilute the goat anti-mouse to 1 μg / ml using coating solution (0.05M carbonate and bicarbonate buffer at pH = 9.5), add 100 μL per well to a 96-well ELISA plate, and coat overnight at 4°C. Wash the plate three times with PBS buffer containing 0.05% Tween-20. Dilute the antibody to 1 μg / ml using diluent (1% BSA, 0.1% PBST), add 100 μL per well to a 96-well ELISA plate, and incubate at 37°C for 30 minutes. Dilute biotin-labeled TPO to 100 ng / mL with diluent, take out the ELISA plate incubated at 37°C, wash the plate three times, add 150 μL of the prepared antibody canine C-reactive protein diluent to the 96-well ELISA plate in row A, add 100 μL of the diluent to each well of the 96-well ELISA plate in rows B to H, take 50 μL of the antibody diluent in the wells of row A, and dilute it 3 times from row B, and incubate at 37°C for 30 minutes. Dilute the avidin labeled with horseradish peroxidase at 1:5000 with diluent, take out the ELISA plate and wash the plate three times, add 100 μL to each well of the 96-well ELISA plate, and incubate at 37°C for 30 minutes. Take out the ELISA plate and wash the plate three times, add the color developing solution, color at room temperature for 3 minutes, add 0.5M sulfuric acid to terminate the reaction, and read the OD450 value on the plate reader.

[0126] The heavy chain variable region of antibody 17# in Example 1 is shown in SEQ ID NO:9, wherein the amino acid sequences of the complementary determining regions on the heavy chain variable region are as follows:

[0127] CDR-VH1:SY(X1)-WMH(X2)

[0128] CDR-VH2:YII(X1)-PTTGYT(X2)-DYNQ(X3)-NFKD

[0129] CDR-VH3:RNY(X1)-RYDGR(X2)-YFDY

[0130] The light chain variable region is shown in SEQ ID NO: 10, wherein the amino acid sequences of the complementary determining regions on the light chain variable region are as follows:

[0131] CDR-VL1:RSSQSIN(X1)-HSNGNT(X2)-YLE

[0132] CDR-VL1:KV(X1)-SNA(X2)-FS

[0133] CDR-VL1:FQ(X1)-GSHVPW(X2)-T

[0134] Based on antibody 17#, mutations were performed at sites related to antibody activity in the complementary determining region, among which X1, X2, and X3 were all mutation sites.

[0135] Table 1 Mutation sites related to antibody activity

[0136]

[0137]

[0138] Table 2 Antibody activity analysis data

[0139]

[0140] As can be seen from the table above, mutation 2 has the best activity effect. Therefore, mutation 2 is used as the backbone sequence to screen other mutation sites with better affinity. Some results are as follows:

[0141] Table 3 Mutation sites related to antibody affinity

[0142]

[0143]

[0144] TPO protein 100ng / ml

[0145] The absorbance value of each mutant OD450 was measured and the results were as follows:

[0146] Table 4 Affinity testing of antibody mutations

[0147]

[0148]

[0149] It can be seen that the affinity of each mutation is higher.

[0150] 2. Stability determination

[0151] The concentration of the antibody of the present invention is 1 μg / ml, and the concentration of the TPO protein is 100 ng / mL.

[0152] The antibodies were diluted in a defined buffer (PBS, 0.05% ProClin TM 300) was heat accelerated at 37℃ for 7 days, and the accelerated antibodies were evaluated by SDS-PAGE and ELISA indirect method, and compared with 4℃ to identify the long-term stability of the antibodies. In addition, the test results were displayed as the deviation between the 4℃ value and the accelerated value by repeated freezing and thawing at -20℃ for 5 times. The measurement results are as follows:

[0153] Table 5 Stability study

[0154]

[0155]

[0156] As can be seen from the above, mutations 2 to 2-35 can be stably stored at 4°C, and their properties remain stable when accelerated at 37°C for 0.5 months (the slight decrease in reactivity does not affect the performance of the reagent), ensuring the performance of the reagent after opening the bottle, thereby ensuring the accuracy and stability of the test results.

[0157] Example 3 Antibody Application Research

[0158] Because the performance of antibody #17 and mutations 2 and 1-30 are comparable, the examples cannot exhaust the effects of all antibodies, and this example selects mutation 2-2 for experiment.

[0159] A. Antibody Humanization

[0160] 1. First, analyze the TPO antigen and mutation 2-2 sequences to determine the characteristics of the sequences---possible epitopes

[0161] 2. Variable region homology modeling

[0162] 3. Energy minimization

[0163] 4. Molecular docking

[0164] 5. Energy minimization

[0165] 6. Compare the variable region sequences and determine the humanized replacement framework. It is best to find an antibody that already has a crystal structure. The following conditions must be met: 1. Sequence similarity: The similarity of the H and L chain sequences is greater than 50% at the same time; 2. Structural similarity: Molecular superposition

[0166] 7. CDR transplantation to humanized framework

[0167] 8. Reversion

[0168] 9. Homology Modeling

[0169] 10. Energy Minimization

[0170] 11. Structural superposition

[0171] 12. The humanized heavy chain and light chain were finally determined, and the humanized antibody was named 17#H.

[0172] B. Expression and purification of humanized antibodies

[0173] 1. The gene sequence was synthesized by Shanghai Bioengineering and constructed into the pCDNA3.4 vector

[0174] 2. Expi293 cell recovery and passaging, inoculate at a density of 1E6 24h before transfection

[0175] 3. On the day of transfection, when the cell density reaches 2-2.5E6 and the cell viability is greater than 98%, transfection begins.

[0176] 4. The plasmid addition amount is 1 μg / ml, the heavy chain to light chain ratio is 1:1, and the plasmid to PEI ratio is 1:3. After mixing, place at room temperature for 15 minutes and add to the pre-prepared cell solution. 37°C, 120rpm suspension culture

[0177] 6. After 24 hours, add feed 1 at a rate of 1%

[0178] 7. Add feed 2 after 48 hours, the addition amount is 2%

[0179] 8. After 5 days of fermentation, the cell viability is greater than 70%, and the samples are collected by centrifugation at 5000 rpm and 4°C.

[0180] 9. Prepare the G column and balance it with 5 column volumes of PBS

[0181] 10. Pass the column at a flow rate of 2 ml / min. After the sample has passed through the column, balance it with PBS for 5 column volumes.

[0182] 11. Elute with 0.5M glycine pH 2.7 and dialyze against PBS buffer.

[0183] 12. After concentration in an ultrafiltration tube, the BCA method was used for quantification, with a concentration of 5 mg / mL.

[0184] C. Antibodies as a tool for TPO purification

[0185] (I) Purification by conventional methods

[0186] The specific steps are as follows:

[0187] 1. 50 mg of 17#H was dialyzed in PBS (pH 7.2) at 4°C for 12 h, and the dialyzate was filtered through a 0.45 uM filter to remove the precipitate.

[0188] 2. Take 5 ml of NHS filler (GE), wash the filler with 50 ml of pre-cooled 1 Mm HCl, and then wash the filler with 50 ml of PBS (pH = 7.2).

[0189] 3. Mix 5 ml of filler and 50 mg of 17#H, mix well and place at 4°C for 12 hours, 50 rpm.

[0190] 4. Recover the filler, add blocking solution (0.5 M ethanolamine pH = 8.0) at a ratio of 1:2, and place at room temperature for 3 hours at 50 rpm.

[0191] 5. Collect the filler and wash it alternately with pH=2.7 glycine eluent and PBS (pH=7.2) for 5 times, 10 ml each time. This is defined as purification and standby.

[0192] 6. Add 15 mL of equilibration buffer (pH = 7.2 PBS) to equilibrate the purification column.

[0193] 7. Start loading 1L fermentation TPO protein supernatant at a flow rate of 5ml / min. After the flow is complete, start balancing with 50ml PBS (pH=7.2).

[0194] 8. Add 10 mL of elution buffer (3 M magnesium chloride, pH = 7.0) for elution, and collect the eluate for elution, and collect the eluate.

[0195] 9. After storage, the purity of TPO antigen was verified by SDS-PAGE. Figure 1 Shown is greater than 95%.

[0196] 10. The purification yield of 17#H was calculated to be 96.8%.

[0197] D. Humanized antibodies as calibrators

[0198] In order to verify the effect of the purified TPO antibody in the immunoassay, the protein calibrator was applied to the kit in this example. Currently, the detection of antibodies mainly includes immunoturbidimetry, immunochromatography, chemiluminescence, etc. Among them, chemiluminescence has the most stringent requirements on the performance of antibodies, so this example chooses chemiluminescence for determination. Chemiluminescence kits can be purchased from the market.

[0199] In this example, the 17#H purified from C was used for the experiment.

[0200] Assay reagents, including R1, R2 and magnetic bead solution

[0201] The R1 includes: biotin-labeled TPO antigen, used at a concentration of 1 μg / ml.

[0202] The R2 includes: alkaline phosphatase labeled protein A, used at a concentration of 0.1 μg / ml

[0203] The specific steps are as follows:

[0204] 1. Experimental preparation: 5 ml each of R1 and R2 working solutions, 4 ml of magnetic bead solution, calibrator, 17# antibody, 17#H antibody.

[0205] 2. Place each component into the kit respectively, and then place the kit into the fully automatic chemiluminescence immunoassay analyzer EXI1800 (from Zhongyuan Huiji Biotechnology Co., Ltd.), and select the anti-TPO project (sample 10μl, R1 60μl, R2 125μl, magnetic bead solution 30μl) for the experiment.

[0206] (1) Linear experiment

[0207] Table 6 Linearity test results

[0208]

[0209] Therefore, the results are shown in Table 6 and Figure 2 As shown, 17#H was used as a calibrator in anti-TPO detection and had a good linear effect.

[0210] Although the embodiments of the present invention have been disclosed as above, they are not limited to the applications listed in the specification and the implementation modes, and they can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily implemented. Therefore, without departing from the general concept defined by the claims and the scope of equivalents, the present invention is not limited to the specific details and the illustrations shown and described herein.

Claims

1. An anti-TPO antibody or a functional fragment thereof, characterized in that: The antibody or its functional fragment comprises the following complementarity determining region: CDR-VH1: S-X1-WM-X2, where X1 is Y or D, and X2 is H; CDR-VH2: YI-X1-PTTGY-X2-DYNX 3-NFKD, wherein X1 is I or N, X2 is S or T, and X3 is Q or S; CDR-VH3: RN-X1-RYDG-X2-YFDY, where X1 is A or Y, and X2 is R or Y; CDR-VL1: RSSQSI-X1-HSNGN-X2-YLE, where X1 is A or N, and X2 is R or A; CDR-VL2: K-X1-SN-X2-FS, where X1 is V or H, and X2 is R or A; and CDR-VL3: F-X1-GSHVP-X2-T, wherein X1 is Q and X2 is W or P.

2. The anti-TPO antibody or a functional fragment thereof according to claim 1, wherein: X2 of CDR-VH1 of the complementary determining region is H, X1 of CDR-VH2 is I, X2 of CDR-VH3 is R, X1 of CDR-VL1 is A, X2 of CDR-VL2 is R, and X1 of CDR-VL3 is Q.

3. The anti-TPO antibody or functional fragment thereof according to claim 1, characterized in that: In the CDR-VH1, X1 is Y; Preferably, X1 in the CDR-VH1 is D; Preferably, in the CDR-VH1, X2 is H; Preferably, in the CDR-VH2, X1 is I; Preferably, in the CDR-VH2, X1 is N; Preferably, X2 in the CDR-VH2 is S; Preferably, X2 in the CDR-VH2 is T; Preferably, X3 in the CDR-VH2 is Q; Preferably, X3 in the CDR-VH2 is S; Preferably, in the CDR-VH3, X1 is A; Preferably, X1 in the CDR-VH3 is Y; Preferably, in the CDR-VH3, X2 is R; Preferably, X2 in the CDR-VH3 is Y; Preferably, X1 in the CDR-VL1 is A; Preferably, in the CDR-VL1, X1 is N; Preferably, X2 in the CDR-VL1 is T; Preferably, X2 in the CDR-VL1 is F; Preferably, in the CDR-VL2, X1 is V; Preferably, in the CDR-VL2, X1 is L; Preferably, X2 in the CDR-VL2 is R; Preferably, X2 in the CDR-VL2 is A; Preferably, in the CDR-VL3, X1 is Q; Preferably, X2 in the CDR-VL3 is W; Preferably, X2 in the CDR-VL3 is P.

4. The anti-TPO antibody or a functional fragment thereof according to any one of claims 1 to 3, characterized in that: Each complementary determining region is selected from any one of the following mutation combinations: 。 5. The anti-TPO antibody or a functional fragment thereof according to any one of claims 1 to 4, characterized in that: The antibody comprises light chain framework regions FR1-L, FR2-L, FR3-L and FR4-L and heavy chain framework regions FR1-H, FR2-H, FR3-H and FR4-H; the heavy chain framework regions FR1-H, FR2-H, FR3-H and FR4-H are selected from SEQ ID NOs: 1-4 in sequence; the light chain framework regions FR1-L, FR2-L, FR3-L and FR4-L are selected from SEQ ID NOs: 5-8 in sequence.

6. The anti-TPO antibody or functional fragment thereof according to claim 5, characterized in that: The antibody further comprises a constant region; Preferably, the constant region is selected from the constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD. Preferably, the species origin of the constant region is cattle, horses, dairy cows, pigs, sheep, goats, rats, mice, dogs, cats, rabbits, camels, donkeys, deer, minks, chickens, ducks, geese, turkeys, fighting cocks or humans.

7. The anti-TPO antibody or a functional fragment thereof according to claim 6, wherein: The antibody is a labeled antibody; Preferably, the labeling substance of the labeled antibody includes but is not limited to biotin, fluorescent dyes, enzymes that catalyze the color development of substrates, radioactive isotopes, chemiluminescent reagents and nanoparticle labels; Preferably, the fluorescent dyes include but are not limited to fluorescein dyes and their derivatives, rhodamine dyes and their derivatives, Cy series dyes and their derivatives, Series dyes and their derivatives, ATTOTM series dyes, TYE series dyes, quantum dots and protein dyes and their derivatives, etc.; Preferably, the enzyme that catalyzes the color development of the substrate includes, but is not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and 6-phosphoglucose deoxidase; Preferably, the radioactive isotopes include but are not limited to 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110mIn, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu and 18F; Preferably, the chemiluminescent reagent includes, but is not limited to, luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, bipyridine ruthenium and its derivatives, acridinium esters and their derivatives, dioxetanes and their derivatives, lophanes and their derivatives, and peroxyoxalates and their derivatives; Preferably, the nanoparticle markers include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles; Preferably, the colloid includes, but is not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex; Preferably, the colloidal metal includes but is not limited to colloidal gold, colloidal silver and colloidal selenium.

8. Use of the anti-TPO antibody or a functional fragment thereof according to any one of claims 1 to 7 in purifying TPO protein.

9. Use of the anti-TPO antibody or a functional fragment thereof according to any one of claims 1 to 7 as a calibration quality control in a kit for detecting TPO antibodies.

10. The use according to claim 9, characterized in that The sample detected by the kit is selected from whole blood, serum, plasma, urine or saliva.

Citation Information

Cited By

  • Anti-thyroid peroxidase antibodies and immunoassays

    WO2026084964A1